We treat cannabis like the industry it is.
CannIntel was founded in 2026 on a simple premise: cannabis is now a serious industry, a serious science, and a serious policy domain — and it deserves journalism written to those standards.
We are not a stoner blog. We are not a strain catalog with affiliate links. We are a small, opinionated newsroom built around five principles:
- Original reporting beats aggregation. Every story should make a reader smarter than the press release they could have read themselves.
- Names attached to bylines. Every CannIntel writer is identified, with biography, beats, and credentials.
- Medical reviewers on medical stories. If we publish a clinical claim, a licensed clinician reviewed it first.
- Speed matters, but accuracy decides. We will be late before we will be wrong.
- Corrections are public. When we get something wrong, we say what we got wrong, when, and how we fixed it.
Who we cover for
We write for the seven distinct audiences this industry actually has — growers, consumers, investors, industry professionals, medical patients, brand operators, and the curious public. Each of those audiences needs a different depth of treatment, and we try to bring the right one to each story.
How we are funded
CannIntel is supported by display advertising, sponsored content (clearly labeled), affiliate partnerships on reviewed products, premium research reports, and our paid newsletter offerings. Sponsored content never receives editorial endorsement. Advertisers never see editorial coverage before publication.
Who runs CannIntel
Our editorial leadership is listed in full on the newsroom page. The editor-in-chief is Marcus Vela. Editorial decisions and corrections are his responsibility.
Contact
News tips: tips@cannintel.com
Corrections: corrections@cannintel.com
Editorial inquiries: newsroom@cannintel.com
Advertising: advertising@cannintel.com